US4216211A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic composition
Assignee: Procter and Gamble Co
•
Filing: 1977-10-31
•
Granted: 1980-08-05
•
Expires: 1997-10-31
Abstract
Abstract Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.
Inventors
- 👤 Marion D. Francis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 11:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
208 words
A process for increasing the level of 2,3-diphosphoglycerate in the blood of a human or lower animal in need of such treatment, comprising administering to said human or lower animal sufficient organophosphonate compound selected from the group consisting of vicinal organophosphonates of the formula ##STR4## and geminal organophosphonates of the formula ##STR5## and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R, R 1 and R 2 are H,--CH 2 OH, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; R 3 is H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is H, lower alkyl, amino, benzyl, halogen, OH, --CH 2 COOH, --CH 2 PO 3 H 2 or --CH 2 CH 2 PO 3 H 2 to increase the blood level of said 2,3-diphosphoglycerate.
Claim 2
Dependent Claim
208 words
A process for increasing the level of 2,3-diphosphoglycerate in the blood of a human or lower animal in need of such treatment, comprising administering to said human or lower animal sufficient organophosphonate compound selected from the group consisting of vicinal organophosphonates of the formula ##STR4## and geminal organophosphonates of the formula ##STR5## and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R, R 1 and R 2 are H,--CH 2 OH, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; R 3 is H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is H, lower alkyl, amino, benzyl, halogen, OH, --CH 2 COOH, --CH 2 PO 3 H 2 or --CH 2 CH 2 PO 3 H 2 to increase the blood level of said 2,3-diphosphoglycerate.
Claim 3
Dependent Claim
28 words
A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 4
Dependent Claim
17 words
A process according to claim 2 wherein the organophosphonate compound is a sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid.
Claim 5
Dependent Claim
28 words
A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanediphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 6
Dependent Claim
28 words
A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanedichlorodiphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-08-05 | 1984-02-04 | 1984-08-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-08-05 | 1988-02-04 | 1988-08-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-08-05 | 1992-02-04 | 1992-08-05 | $7700.00 | Window Closed / Lapsed |